Co-Authors
This is a "connection" page, showing publications co-authored by Max Crispin and Joel Allen.
Connection Strength
2.837
-
Site-Specific Steric Control of SARS-CoV-2 Spike Glycosylation. Biochemistry. 2021 07 13; 60(27):2153-2169.
Score: 0.954
-
Subtle Influence of ACE2 Glycan Processing on SARS-CoV-2 Recognition. J Mol Biol. 2021 02 19; 433(4):166762.
Score: 0.919
-
Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine. ACS Cent Sci. 2021 Apr 28; 7(4):594-602.
Score: 0.234
-
Vulnerabilities in coronavirus glycan shields despite extensive glycosylation. Nat Commun. 2020 05 27; 11(1):2688.
Score: 0.221
-
Site-specific glycan analysis of the SARS-CoV-2 spike. Science. 2020 07 17; 369(6501):330-333.
Score: 0.220
-
Development of a high-sensitivity ELISA detecting IgG, IgA and IgM antibodies to the SARS-CoV-2 spike glycoprotein in serum and saliva. Immunology. 2021 09; 164(1):135-147.
Score: 0.059
-
SARS-CoV-2-specific IgG1/IgG3 but not IgM in children with Pediatric Inflammatory Multi-System Syndrome. Pediatr Allergy Immunol. 2021 07; 32(5):1125-1129.
Score: 0.059
-
Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. Cell. 2021 03 04; 184(5):1188-1200.e19.
Score: 0.058
-
Sensitive Detection of SARS-CoV-2-Specific Antibodies in Dried Blood Spot Samples. Emerg Infect Dis. 2020 12; 26(12):2970-2973.
Score: 0.057
-
SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study. Thorax. 2020 12; 75(12):1089-1094.
Score: 0.056